Hovnanian HOVNP Reports Strong Q1 2026 Revenue NA EPS Beats Popular BPOP Q1 2026 Beat Revenue NA EPS Exceeds by Significant Trumps Approval Rating Drops to 35 as Republican Support Weakens Market Implications Ovid Therapeutics OVID Drops 167 Key Support at 224 20260520 Trumps Grip on Republican Party Tightens After Massie Defeat Implications for Markets and Policy Zydus Lifesciences Shares Gain on Robust Q4 Results with Buyback Announcement